Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp raised its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 22.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 129,845 shares of the medical research company's stock after purchasing an additional 23,729 shares during the period. Mackenzie Financial Corp's holdings in Edwards Lifesciences were worth $9,612,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of EW. Sivik Global Healthcare LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $3,702,000. Farmers & Merchants Investments Inc. boosted its position in shares of Edwards Lifesciences by 21.1% during the 4th quarter. Farmers & Merchants Investments Inc. now owns 134,341 shares of the medical research company's stock valued at $9,945,000 after acquiring an additional 23,409 shares during the last quarter. Lockheed Martin Investment Management Co. purchased a new position in Edwards Lifesciences in the fourth quarter worth $4,499,000. Union Bancaire Privee UBP SA purchased a new position in Edwards Lifesciences in the fourth quarter worth $1,120,000. Finally, OLD National Bancorp IN grew its position in Edwards Lifesciences by 3.7% in the fourth quarter. OLD National Bancorp IN now owns 197,143 shares of the medical research company's stock worth $14,594,000 after acquiring an additional 7,066 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on EW. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Morgan Stanley increased their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.36 during mid-day trading on Friday, hitting $78.09. The stock had a trading volume of 9,048,502 shares, compared to its average volume of 5,183,306. The firm has a market capitalization of $45.81 billion, a P/E ratio of 11.20, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm's 50 day moving average is $73.22 and its 200 day moving average is $72.33. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the firm posted $0.66 EPS. The company's revenue was up 6.2% on a year-over-year basis. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the transaction, the vice president now owns 33,496 shares in the company, valued at $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,442 shares of company stock worth $4,025,799 over the last ninety days. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.